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Abstract
The maturation of genomic technologies has enabled new discoveries in disease pathogenesis as
well as new approaches to patient care. In pediatric oncology, patients may now receive individu-
alized genomic analysis to identify molecular aberrations of relevance for diagnosis and/or treat-
ment. In this context, several recent clinical studies have begun to explore the feasibility and utility
of genomics-driven precision medicine. Here, we review the major developments in this field, dis-
cuss current limitations, and explore aspects of the clinical implementation of precision medicine,
which lack consensus. Lastly, we discuss ongoing scientific efforts in this arena, which may yield
future clinical applications.
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1 INTRODUCTION
1.1 Medicine and society: the precisionmedicine era
Precision medicine is broadly defined by the National Institutes of
Health as “an emerging approach for disease treatment and preven-
tion that takes into account individual variability in genes, environ-
ment, and lifestyle for each person.” The Obama administration’s Jan-
uary 2015 announcement of the Precision Medicine Initiative (PMI)
takes a step forward in efforts to move precision medicine into clin-
ical practice.1 With $215 million in planned funding for fiscal year
2016, the PMI aims to leverage next-generation sequencing capabili-
ties, improved biospecimen analytics, and tools for themanagement of
large data sets to generate outcome data that will facilitate movement
from the research realm into clinical care. Recently, the National Can-
cer Moonshot Initiative, announced by President Obama during the
2016 State of the Union address and motivated by the death of Vice
President Joseph Biden’s son to brain cancer, has proposed expand-
ing governmental involvement and financial support upwards of
$4 billion.2
Indeed, across multiple disciplines, the widespread utilization of
high-throughput genomic technologies has enabled more detailed
clinical characterization and management according to genomic
knowledge. In pulmonology, patients with cystic fibrosis having
the pathogenic CFTR G551D mutation preferentially respond to
the drug ivacaftor.3 Cardiovascular medicine has 12 drugs with
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F IGURE 1 An overview of precision medicine in oncology. Patients
are enrolled for genomic profiling following informed consent. Tumor
samples are then acquired, processed, molecularly profiled (typically
through sequencing), and analyzed computationally. Molecular results
are reviewed in a precision medicine tumor board prior to disclosure
of selected, relevant results to the patient. Where available, targeted
therapies may be initiated based onmolecular findings
pharmacogenetic labeling from the FDA, and genotype data are help-
ing to better predict risk for cardiovascular disease and character-
ize disease subtypes. Identification of patients with mutations linked
to familial hypercholesterolemia, arrhythmias, and cardiomyopathies
creates opportunities for prevention of myocardial infarction and sud-
den cardiac death.4 Researchers in gastroenterology are using preci-
sion medicine tools to improve biomarkers for numerous diseases and
are interrogating the microbiome environment in gastrointestinal dis-
ease. In the intensive care unit, researchers have begun to define clin-
ically feasible assays to rapidly detect sepsis through accumulation of
specificmetabolites in blood.5
1.2 Precisionmedicine and cancer
While the tools of precision medicine are being applied broadly, can-
cer has been at the vanguard of these efforts (Fig. 1), and near-
term goals of the PMI are most accessible in oncology. The emer-
gence of biomarker-driven targeted therapies is already a reality for
some oncology patients. Thus, patientswith lung cancer having epider-
mal growth factor receptor (EGFR) alterations receive EGFR-targeting
therapies,6 whereas those with anaplastic lymphoma kinase (ALK)
alterations receive ALK-targeting therapies.7 Furthermore, as molec-
ular subclasses of cancer are established, clinical study design has
adapted accordingly, moving toward umbrella designs or biomarker-
driven study in which patients are enrolled based on molecular fea-
tures. The National Cancer Institute (NCI), which is leading the Moon-
shot Initiative efforts, has outlined several areas of focus for ongo-
ing oncology PMI research and implementation: expanding clinical
study, enhancing drug discovery and development, developing new cell
line models, furthering the promise of immunotherapy, and improv-
ing early detection and prevention through vaccines, chemopreven-
tion, and biomarker discovery.2 Moreover, pediatric cancer has been
emphasized as a specific target area for advancing precision medicine
into clinical care.
2 EARLY CLINICAL STUDIES IN PEDIATRIC
ONCOLOGY
At diagnosis, patients with pediatric cancer tend to have lower
rates of mutation across their genomes when compared against all
adult cancers.8–10 By contrast, pediatric tumors that are treatment-
refractory and recurrent, generally have higher mutation rates, more
comparable to adult tumors.11–13 These data can be used to support
claims that, at diagnosis, there may be less molecular complexity per
individual cancer, which may enable efficacy for targeted agents by
decreasing thenumberof altered cellular pathways, aswell as the claim
that there are generally few recurrently mutated targetable genes in
pediatric cancers, which may limit the availability and use of some tar-
geted agents. The relative paucity of targetablemutations in pediatrics
is compounded by limited access to newer targeted therapeutic agents
due to the availability of fewer pediatric clinical studies and smaller
number of eligible patients for each study.
Despite these challenges, initial pilot studies of genomic medicine
in pediatric oncology have been both fruitful and encouraging
(Fig. 2),with severalmajor conclusions. First, althoughpediatric tumors
typically lack frequent targetable kinase alterations such as those in
common adult cancers such as lung (EGFR) or breast cancer (HER2),
pediatric tumors appear to be enriched for targetable gene fusions.
Second, there has been a surprising frequency of rare mutations in
actionable genes in unexpected tumor types.14 Third, the studies have
reemphasized the importance of pathogenic germline mutations in
pediatric cancers, even among patients lacking a notable family his-
tory of cancer. Finally, there have been notable cases of patients with
a change in diagnosis or risk stratification due to genomic aberrations
discovered onmolecular testing.
Next,we summarize the early findings from four key pediatric preci-
sion oncology studies, including two from the NHGRI and NCI-funded
Clinical Sequencing Exploratory Research (CSER) program15–17 (Table
1). All of these studies are still ongoing and we will await the results
of a larger, more definitive cohort in future. For readers less familiar
with genome sequencing technologies, we have included Supplemen-
tary Appendix S1 that details the basic modalities, their pros and cons,
and their compatibility with different biospecimen types.
2.1 PEDS-MIONCOSEQ
The University of Michigan Pediatric Michigan Oncology Sequencing
(PEDS-MIONCOSEQ) study15 is based on their earlier adult sequenc-
ing efforts.18 The results from the first 102 patients enrolled on PEDS-
MIONCOSEQ have now been reported.15 Primary study population
included pediatric and young adult patients with cancer having refrac-
tory, relapsed disease, while 20% cases included had newly diagnosed
high-risk or rare disease, all of whom had undergone extensive testing
by the available standard of care testing.Majority of these patients had
either failed or had no proven therapeutic options available to them
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F IGURE 2 Molecular data in precision oncology. Pediatric cancers
may harbor clinically relevant germline and somatic variants, copy
number aberrations, gene fusions, and gene expression patterns. Here,
the outer circle indicates the type of molecular event. The middle
circle indicates the various molecular assays used to profile a given
molecular event. The inner circle provides several examplesof clinically
relevant findings enabled by molecular profiling. WES, whole exome
sequencing; WGS, whole genome sequencing; cDNA, complementary
DNA; Mut, mutation; Amp, amplification; Del, deletion; Indel, inser-
tion/deletion; SNV, single-nucleotide variant; aCGH, array compara-
tive genome hybridization
andwere looking for novel therapies. Thiswas one of two studies along
with INFORM that included all subtypes of pediatric malignancies
including hematopoietic, brain, and solid tumors. Ninety-one patients
underwent genomic analyses with whole exome sequencing (WES)
of tumor and germline DNA as well as RNA sequencing of tumor
RNA. Clinical decision-making was made through a multidisciplinary
tumor board, and patient follow-up was updated quarterly. Typical
turnaround time and cost estimates were 54 days and $6,000, respec-
tively. Overall, 42 patients (46%) had potentially actionable findings,
most of which were not detected by standard diagnostic tests that
did not include sequencing. The actionable findings included 9 patients
with germline findings, 10 patients with an actionable gene fusion
found via RNA-seq, and 2 patients who had their diagnosis changed.
Twenty-three patients had an individualized care decisionmade based
on sequencing results, which included 14 patients receiving differ-
ent therapies, 9 patients with genetic counseling, and 1 patient with
both. Nine of 14 patients with a change in management had a clinical
response lastingmore than 6months in duration.
2.2 Basic3
Data have been reported for the first 150 children with solid and
brain tumors enrolled on the Baylor College of Medicine Advancing
Sequencing in Childhood Cancer Care (BASIC3) study.16 All patients
underwent germline WES and those with available tumor (121/150;
81%) also underwent tumor WES. Unique among pediatric studies
to date, the BASIC3 study included only newly diagnosed, untreated
patients. The clinical relevance of sequencing findings was described
using a standardized scale defined by the study investigators. In total
47 of 121 (39%) patients who underwent both tumor and germline
sequencing were considered to have a potentially clinically relevant
finding. Four of 121 (3%) patients harbored a category I somatic muta-
tion (i.e., known pathogenic in that disease), and 29 of 121 (24%) had
a category II somatic mutation (i.e., a gene of potential clinical rel-
evance, including known targetable genes). Fifteen of 150 patients
(10%) undergoing germline sequencing had a diagnostic germline find-
ing related to their phenotype (cancer and/or other diseases), includ-
ing 13 (8.6%) with pathogenic or likely pathogenic mutations in known
cancer susceptibility genes. No patients were treatedwithmolecularly
targeted agents based on study results.
2.3 iCat
The Individualized Cancer Therapy (iCat) study is a multi-institutional
effort coordinated through Dana-Farber/Boston Children’s Hosp-
ital,19 with the sequencing results of 101 extracranial patients with
solid tumor reported, including 80% with recurrent or refractory dis-
ease looking for novel therapeutic options. Molecular profiling was
completed on tumor tissue DNA for 89 patients. Molecular profil-
ing was performed with a heterogeneous variety of techniques: 13
patients via OncoMap alone (a Sequenom assay for 41 genes), 27
patients by OncoMap and array comparative genomic hybridization
(aCGH), 25 patients by OncoPanel (targeted Illumina sequencing for
275 genes and 91 introns for rearrangements) and aCGH, and 24
patients byOncoPanel alone. Clinical recommendationswerebasedon
consensus opinion with members of the multidisciplinary panel rank-
ing potential findings on a 1 (strongest) to 5 (weakest) scale. In total,
31% of patients received iCat recommendations and 43% of patients
were judged to have findings of clinical significance, including frequent
focal copy number alterations (20 of 39 total clinically relevant find-
ings), themajority ofwhichwereMYC/MYCN amplifications detectable
by conventional methods. Three patients (3%) were treated with tar-
geted therapies based on study findings, but there were no objective
responses. Three patients had a change in disease diagnosis based on
tumor profiling.
2.4 Inform
The Individualized Therapy for Relapsed Malignancies in Childhood
(INFORM) study is a multi-institutional German effort coordinated
through the German Cancer Research Center (DKFZ).20 Fifty-seven
patientswereenrolled (50 relapsed/refractory and7primarypatients),
of whom 52 received molecular profiling. Molecular profiling was
performed with WES and RNA-seq. Low-coverage whole genome
sequencing (WGS) was used for copy number events; DNA methy-
lation and gene expression microarrays were also performed. Typ-
ical turnaround time and cost estimates were 28 days and €7,000
(∼$8,000), respectively. Clinical recommendations were based on a
standardized, seven-step scoring algorithm to prioritize molecular tar-
gets. In total, 26 patients (50%) had a clinically relevant finding (limited
MODY ET AL. 5 of 14
to fusions, gene expression, copy number, and mutations/indels; DNA
methylation was not directly used). Two (4%) patients had a germline
finding that supported a cancer predisposition syndrome. Ten (19%)
patients had treatments altered based onmolecular findings, including
two (4%) patients who had prolonged tumor response>6months. Five
(10%) patients had a change in diagnosis based on tumor profiling.
3 LESSONS FROM THE EARLY STUDIES
There are several important issues highlighted by these studies. First,
clinical genomic analysis has the potential to identify potentially clini-
cally relevant alterations in a substantial fraction of patientswith pedi-
atric cancer as demonstrated by all four studies. Second, both tumor
and germline alterations identified in these studies target a diverse set
of genes, including many that were not previously known to be associ-
ated with the patient’s cancer type or in pediatric cancer, emphasizing
the potential yield of genome-scale testing for these patients.
Third, the PEDS-MIONCOSEQ and INFORM studies demonstrate
the utility of RNA-seq to identify actionable gene fusions. In the PEDS-
MIONCOSEQ study, 33 of 91 patients had a driver gene fusion, 10
of which were actionable. In the INFORM study, 5 of 52 patients
had an actionable gene fusion. While the iCat study attempted to
identify translocations via DNA sequencing of targeted introns, this
method was not particularly effective. Only one targetable translo-
cation was found, which is surprising given that the iCat study had
very high proportion of patients with sarcoma (n = 61). By con-
trast, the PEDS-MIONCOSEQ and INFORM studies had directly tar-
getable fusions in 5 of 44 patients with sarcoma. Fourth, there were
10 patients collectively in the iCat, PEDS-MIONCOSEQ, and INFORM
studies whose diagnosis was changed by tumor profiling, which is sig-
nificant given the detailed pathologic review each patient had as part
of clinical evaluation, including many of the refractory patients being
reviewed bymore than one treating center before enrollment on these
studies.
Fifth, the PEDS-MIONCOSEQ, INFORM, and iCat studies demon-
strated the potential utility of genomics to guide selection of tar-
geted therapies. While the PEDS-MIONCOSEQ and INFORM studies
demonstrated that a small set of patients (n = 9 (10%) and 2 (4%),
respectively) had a clinical response following initiation of a targeted
therapy, iCat study failed to show objective responses in their patient
population (n = 3). The difference is most likely due to the biologi-
cal nature of malignancies and genomic lesion being targeted. PEDS-
MIONCOSEQ and INFORM responders included patients with single-
nucleotide variant or actionable fusion in hematological malignancies
and actionable fusions in solid tumors, which historically have shown
to be more responsive to single agent targeted therapy. In compari-
son, all three iCat patients who were treated based on study recom-
mendations were patients with refractory solid tumor having muta-
tions in FGF, PI3K, and ALK pathway and were treated with a single
agent targeted therapy. These differential responses to single agent
targeted therapy highlight the importance of optimal patient selection,
role of RNA-Seq in genomic analysis of pediatric patients, and role of
multiagent-targeted therapy for the hardest to treat refractory solid
tumors. In contrast, the BASIC3 study highlights spectrum of genomic
changes in newly diagnosed and untreated patients but did not require
change in management based on the study results, as it would be eth-
ically and logistically very challenging to integrate targeted therapy in
combination with or instead of standard frontline therapy.
Lastly, these studies highlight the prevalence of pathogenic
germline mutations: roughly 10% in both PEDS-MIONCOSEQ and
BASIC3, and 4% in INFORM, while iCat study did not specifically
address germline mutations. These data are consistent with the
recent data from the Pediatric Cancer Genome Project (PCGP), a
collaboration between St. Jude andWashington University with a goal
to characterize pediatric cancer genomes.21 By analyzing germline
sequencing data of 1,120 patients for 60 known cancer predisposition
genes, the PCGP found that there was an overall 8.5% prevalence of
likely pathogenic variants in the germline of patients with pediatric
cancer.14 In addition, almost half of these patients with pathogenic
variants in both PEDS-MIONCOSEQ and PCGP studies had no sig-
nificant family history. This information is of great significance to
providers caring for patients as well as for their families, as most of
these parents and siblings are in relatively younger age group and
would benefit from early screening.
4 MOLECULAR TARGETS IN PEDIATRIC
CANCERS
While molecular targets in adult tumors have been the focus of
most pharmaceutical efforts,22 pediatric patients have largely not yet
benefited from these due to limited overlap with molecular events
driving adult tumors, small number of patients, and safety concerns
in young children. However, this is beginning to change as we start
to catalogue actionable events driving pediatric tumors through pre-
cision oncology studies discussed earlier and other efforts.9,11,21,23 A
selection of most common molecular events and targeted agents are
detailed in Table 2.24–46
Extending the utility of drugs initially developed for adult can-
cers and repurposing them for pediatric tumors sharing the same
target have become a major source of new clinical studies for
pediatrics, and there are several particularly notable examples.
First, crizotinib, initially promoted in ALK fusion-positive lung
cancers,47 has demonstrated impressive responses in patients with
a variety of molecular aberrations (ALK, NTRK1/2/3, and ROS1
translocations) as well as in different tumor types, for exam-
ple, anaplastic large cell lymphoma, inflammatory myofibroblastic
tumors, neuroblastoma, and sarcomas.15,33 Second, for brain tumors,
SMO inhibitors such as vismodegib, first developed for basal cell
carcinoma,48 have demonstrated promise for medulloblastoma
patients with PTCH1 mutations.36,49 Third, PARP1 inhibitors, which
were initially applied toBRCA1/2mutant breast and ovarian cancers,50
are being explored as a therapeutic strategy for patients with Ewing
sarcoma having EWSR1-FLI1 fusions,37,38 although initial studies of
olaparib monotherapy suggest that its activity as a single agent is
limited.51,52 Lastly, a number of excitingmolecular strategies for treat-
ing neuroblastoma are being investigated, such as CDK4/6 inhibitors
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TABLE 2 Targeted agents in pediatric cancers
Inhibitor







































































AURKA MYCN amplification Alisertib Neuroblastoma 46







FLT3mutation or internal tandem
duplication
Sorafenib Acutemyeloid leukemia 43,44
VEGFR, cKit, PDGFR expression Pazopanib Sarcomas 45
aLoss refers to genomic loss through either deletion or inactivatingmutation.
and aurora kinase inhibitors, both of which have shown selectivity for
MYCN-amplified cell lines in vitro.39
5 DRUG AVAILABILITY IN PEDIATRIC
ONCOLOGY
Access to pediatric oncology drugs is unfortunately not a new prob-
lem. There have been prior issues with shortages in anticancer
agents,53 which have prompted discussion bymany institutions includ-
ing the Food and Drug Administration (FDA).54 For new discov-
eries, methods to incentivize pharmaceutical companies have been
extensively discussed,55 and there are two existing laws that pro-
mote pediatric drug development—the Best Pharmaceuticals for
Children Act (BPCA) and Pediatric Research Equity Act (PREA).
The BPCA offers additional patent exclusivity for on-patent drugs
tested for pediatric use. The PREA enables the FDA to mandate
pediatric drug studies as a last resort if other incentives do not
succeed.
Recently, accelerated FDA approval of “breakthrough” drugs, such
as crizotinib,56 has generated much interest and discussion.57,58
Because of such extraordinary examples of targeted agents, “seam-
less” or “first-in-human” studies, which are streamlined and do not
employ traditional phase 1/phase 2/phase 3 paradigms, have been
used on more than 40 oncologic therapies.59 These studies may pro-
vide a basis to test novel compounds in pediatric patients more
quickly. However, accelerated study designs also have significant
limitations when applied for pediatrics, including lack of control
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group and poor ability to identify toxicities, particularly in an age-
dependent fashion. Ultimately, while modified study design may help,
increased access to targeted therapies will also require greater col-
laboration with industry to move experimental therapeutics into
the clinic for childhood cancers via traditional clinical studies as
well.
6 LOGISTICAL CHALLENGES IN
PRECISION ONCOLOGY
6.1 Cost
Genomic profiling of patients with pediatric cancer presents numer-
ous challenges (Table 3)—the first challenge is cost. The PEDS-
MIONCOSEQ study had a cost of $6,000 for WES and RNA-Seq with
about half the amount spent for biochemical reagents and the other
half for computational analyses, laboratory personnel, and capital
depreciation.15,60 The INFORM study had a cost of €7,000 (∼$8,000),
which includedWES, RNA-seq, low-coverage WGS, a gene expression
array, and a DNA methylation array.20 However, these cost estimates
are probably lower than the actual costs, as it does not include the
time spent in clinical analysis, annotation, discussion, and deliberation
on the results. On the other hand, traditional sequencing assays, such
as BRCA gene sequencing, can cost up to $5,000 for a single gene or
small panel of genes, thus making a genome-wide approachmore cost-
effective.61
The cost of reagents is going down, however the future cost
of sequencing may not come down significantly due to ris-
ing bioinformatics costs deriving mainly from (i) data storage,
(ii) computational pipeline generation, and (iii) data processing
time.60,62,63 Indeed, data storage and processing time are increas-
ingly facilitated through cloud computing, which is a pay-for-service
paradigm.
In addition to the cost of reagents and computational resources,
there are also considerable costs for a clinical genomic infrastructure,
including increasedpersonnel such as technologists, bioinformaticians,
and genetic counselors. Building a genomics team to generate and ana-
lyze sequencing data therefore requires institutional support from the
hospital or healthcare system. Likewise, there may be costs associ-
ated with training physicians to understand genomic data and reports
through ongoingmedical education.
6.2 Turnaround time
The median-reported turnaround time for PEDS-MIONCOSEQ and
INFORMstudieswere54and28days, respectively,while other studies
did not report the time.15,20 Reductions in turnaround time will likely
result through streamlined computational analyses, which at present
can take up to 4 weeks. This may be lessened through targeted anal-
yses, which focus only on a limited set of genes. Ultimately, the most
promising way to reduce turnaround time will likely stem from opti-
mized computational pipelines that process data more quickly and in
a parallelized fashion.62,63
6.3 Obtaining adequate tumormaterial
Genomic profiling requires sufficient tumor material from biopsy or
resection. The tumor material also needs to be of sufficient quality
(e.g., not fully necrotic tissue). Given these considerations, some chil-
dren have undergone invasive procedures (e.g., biopsy) for the sole
purpose of obtaining material for genomic testing. While there have
been no major patient complications reported to date, there is a pos-
sibility of complications for any procedure. As sequencing methods
improve,we anticipate that the need for additional biopsieswill be low,
due to improved ability to molecularly profile formalin-fixed, paraffin-
embedded (FFPE)-archived tissue or by further optimization of liquid
biopsy techniques.
6.4 Rational combination of targeted therapies
Even when a targeted therapy is potentially available for a particu-
lar patient, the optimal way to implement this treatment is unclear.
For example, early lessons with the use of cytotoxic chemother-
apy showed us the benefits of rationale combination in treatment
of cancer and many in the scientific community assume the same
with targeted agents. However, we need more rigorous preclini-
cal and clinical testing to understand better, which are the opti-
mal agents to combine for each molecular aberration and with least
toxicity. The combination therapy is likely to include multiple tar-
geted agents or targeted agents in combination with chemotherapy,
radiation, or immunotherapy, and it will most likely depend on the
molecular aberration, tumor type being treated, and host immune
response.
Recently, the SHIVA, a phase-II randomized study in adults with
refractory solid tumors, offered a cautionary tale.64 All included
patients harbored a molecular alteration within one of three path-
ways (hormone receptor, PI3K/AKT/mTOR, and RAF/MEK). Eleven
molecularly targeted agents for these pathways were available.
Patients were randomized to receive a targeted agent as monother-
apy or standard therapy via physician’s choice. With a median follow-
up of 11 months, progression-free survival was not different between
the two groups.
The SHIVA study has been cited by skeptics to argue that the
efficacy of precision medicine may be low.65 However, the SHIVA
study should be interpreted with caution due to multiple serious
limitations. Perhaps most importantly, it is probably unrealistic to
expect that multiply refractory metastatic cancers will respond to tar-
geted agent monotherapy; these tumors have many different path-
ways dysregulated. In addition, their next-generation sequencing
panel was very limited making it likely that a true driver molecu-
lar event was missed. Nonetheless, the SHIVA study does suggest
that the patient selection, choice of sequencing panel, and avail-
able targeted agents will play an important role in practice of pre-
cision oncology. In addition, it is certainly possible that the popula-
tions most likely to benefit from targeted agents might be treatment-
naïve tumors in which pathway addiction is likely stronger and we will
need similar studies in newly diagnosed patients to test its clinical
utility.
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TABLE 3 Challenges in precisionmedicine
Current Status Considerations Future possibilities
Challenges Costa $6,000 • $3,000 in direct sequencing costs
• $1,000 for library preparation
• $2,000 lab personnel, capital cost
• Reductions in sequencing reagents
• Reduced reliance on fee-for-service
computational services
Turnaround timeb 4–6weeks • 1–2weeks for sequencing
• 2–4weeks for bioinformatics
Optimizing computational pipelines with
targeted analyses for time reductions
Lack of clinical
trial availability




data available for many
experimental therapies






initiated in the relapse
settingmostly as a single





• Introduction of targeted agents early in
disease course






∼8–10% of patients harbor
likely pathogenic variants
Flexible default model of optional
disclosure of germline findings to
families
• Increased access for “trio” testing of
families to define variants
• Longitudinal studies on the impact of
findings on families (e.g., psychological,
access to care and adherence to cancer
screening)
aEstimate for supplies and capital depreciation for the PEDS-MIONCOSEQ study byMichigan group (Ref.15) only and does not include cost of analysis.
bTurnaround time estimates refer to the PEDS-MIONCOSEQ study byMichigan group (Ref.15) only.
6.5 Defining pathogenic variants in pediatrics
Relatively few variants have been specifically characterized to val-
idate their pathogenicity. This leads to a challenge when tumor
profiling produces variants that have not been specifically tested
experimentally. To address this, the American College of Medi-
cal Genetics and Genomics (ACMG) updated its terminology for
sequence variants in 2015.66 The Human Genome Variation Soci-
ety (HGVS) similarly has guidelines for terminology.67 These guide-
lines distinguish criteria that are “pathogenic” compared to those that
are “likely pathogenic,” “likely benign,” “benign,” or “uncertain signifi-
cance.”Numerous efforts, including the SomaticCancerworking group
of the Clinical Genome Resource (ClinGen), are currently focused
on the challenge of defining standards for interpretation of somatic
changes and their clinical actionability.68
In practice, most clinical sequencing groups (BASIC3 and PEDS-
MIONCOSEQ) employ centralized sequence variant databases, gener-
ally ClinVar,69 bioinformatics algorithms for prediction of pathogenic
variants, such as PolyPhen-2,70 as well as expert opinion.15,16 One
major challenge, both clinically and scientifically, is presented by vari-
ants of uncertain significance both for somatic and germline variants.
For germline variants, there is no efficient way currently to interpret
these variants, and they are generally discarded from clinical consider-
ations unless so-called “trio” testing (mother, father, and affected child)
is available, whichmay provide useful information for interpretation of
a given variant in a pediatric patient. Recent challenges and scrutiny in
cardiology, in which there are now doubts regarding the pathogenicity
of germline variants in some inherited arrhythmia syndromes,4,71 high-
light the unclear nature of many genomic variants.
6.6 Ethical challenges of germline findings
There have been many discussions of the ethical implications of
germline genome profiling for pediatric cancers,72–75 as well as the
discussion of how best to share genomic information with
patients.76,77 The chance of finding incidental germline pathogenic
variants, defined as a variant that was unrelated to cancer or other
known patient phenotype creates an ethical challenge for these
patients. Indeed, in the BASIC3 study, eight patients (5%) were found
to have such a pathogenic germline variant. Similarly, a recent analysis
of the 1000 Genomes Project, which sequenced 1,000 adult genomes,
found a 2.3% prevalence for incidental findings.67 In response to this,
some groups (e.g., PEDS-MIONCOSEQ) employ a flexible default
consent model in which parents can decide whether they wish to
receive results pertaining to pathogenic germline variants. In the
case of PEDS-MIONCOSEQ, a majority of parents (>80%) did wish to
receive these results.
Even so, there is a risk that germline discoveries in a child may
enable a potential for genetic discrimination in future, particularly for
germline variants not related to cancer or childhood disease gener-
ally. While genetic counselors are routinely involved with families and
patients for whom a heritable cancer syndrome is suspected, it is not
clear that genetic counselors should be involved in cases of inciden-
tal germline findings that do not pertain to cancer. At the same time,
for a child with cancer, who also has a complexmedical condition with-
out a known underlying genetic diagnosis, it is possible that an inci-
dental germline finding may elucidate a unifying genetic diagnosis for
an underlying medical syndrome. Ultimately, it may be most prudent
to leave the decision of disclosure of incidental germline findings to
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parents and patients, though explicit counseling on the risks of this
decisionmust be addressed prospectively.
6.7 Universalization of practice
The implementation of precision medicine is currently uneven and
lacks standardization. There are numerous aspects of healthcare
infrastructure, which will ultimately impact the dissemination of
precision medicine practices, including access to biomarker tests
and therapies, integration with electronic healthcare records, estab-
lishment of national databases, and standardized regulatory and
reimbursement processes, among others.78 While such topics are
beyond the purview of this review, the National Academy of Sci-
ences has been active in discussing mechanisms to expand and
standardize precision medicine through a rational, best-practices
perspective.78 Recently, the Institute of Medicine (IOM) assem-
bled a Committee on Policy Issues in the Clinical Development
and Use of Biomarkers for Molecularly Targeted Therapies.79 In
their report, the Committee has advocated for increased involve-
ment and regulation by the secretary of Health and Human Services
(HHS), in conjunction with the FDA, to standardize biomarker testing
nationally.80
7 DEBATED TOPICS
7.1 Design and role of the precision tumor board
Although incorporated into all clinical sequencing efforts to date, the
design of precision medicine tumor boards varies significantly. While
all tumor boards have included clinical faculty in hematology/oncology
and scientific experts in sequencing, the PEDS-MIONCOSEQ and
BASIC3 studies also incorporated clinical cancer geneticists upfront as
coremembers of the tumor board.15,16 The PEDS-MIONCOSEQ study
also has clinical ethicists as core members.15 Methods to interpret the
data also vary. For example, in the iCat study, members of the expert
panel rank each actionable alteration in each patient, using a for-
mal system.19 By contrast, other groups (PEDS-MIONCOSEQ) discuss
clinical sequencing findings, but do not have formal ranking systems.
7.2 Implementation of DNA sequencing
A version of DNA sequencing (e.g., WES or mutation panels) is an
important component for any precision medicine sequencing panel.
However, the precise implementation of DNA sequencing varies
between groups, and which is the most optimal approach is still not
clear. The BASIC3 study analyzed the entire exome for somatic and
germline mutations. Other groups performed WES but focus compu-
tational analyses to a list of known cancer genes (PEDS-MIONCOSEQ,
PCGP, INFORM). Lastly, some advocate for targeted sequencing of
only cancer-relevant genes and not sequence the whole exome (the
OncoMap andOncoPanel approaches in the iCat study).
7.3 RNAseq or no RNAseq?
The role of RNA sequencing is even less clear. The use of RNA is
associated with additional challenges, including (i) technical difficul-
ties in extracting high-quality RNA from tissue samples, (ii) analyti-
cal complexities of tumor–stroma mixtures in which the fraction of
gene expression from each cell type is difficult to ascertain, and (iii)
increased cost and time of the sequencing and computational analysis.
Nevertheless, RNA sequencing also enables invaluable analyses. These
include comprehensive gene fusion discovery, tumor expression sub-
groupanalysis (e.g.,medulloblastoma subgroups andPh-like acute lym-
phoblastic leukemia), and cell-of-origin gene expression analyses for
tumors of unknown primary. Given the clinical benefit of the discov-
ery of actionable gene fusions, especially in pediatric leukemias and
sarcomas,15,20 we advocate for the inclusionofRNAsequencing in pre-
cision oncology for pediatric cases.
7.4 Standardizing the term “actionable findings or
clinically relevant”
All the pediatric precision oncology studies reviewed here used the
term “actionable findings” or findings of “clinical relevance” to mea-
sure the impact of the study. However, the definition of these terms
was variable between studies. While all studies included “druggable”
genomic alterations in these categories, only PEDS-MIONCOSEQ,
iCat, and BASIC3 included alterations that are not druggable, but
impacted diagnosis, prognosis, or risk stratification as actionable or
clinically relevant. In addition, only PEDS-MIONCOSEQ and BASIC3
considered pathogenic germline variants as actionable findings, with
only BASIC3 considering noncancer-related germline findings as
actionable.
There is a definite need for standardizing the reporting on what are
considered actionable or clinically relevant findings, both in somatic
and germline sequencing. In addition, the somatic findings need further
prioritization based on the strength of clinical evidence and germline
findings needs subclassification into actionable (i) cancer-related, (ii)
noncancer-related, and (iii) pharmacogenomics findings. Finally, we
must recognize that as we identify new targets and develop new
agents, the fraction of patients, which are considered actionable, is
likely to change.
7.5 Subclone detection
Cancer is a multiclonal disease. Pediatric leukemias and sarcomas typ-
ically harbor at least two distinct genetic clones at diagnosis, with
the dominant clone representing ∼70–95% of tumor cells.81–83 Brain
tumors, such as medulloblastoma, generally present with one over-
whelming dominant clone (>95% prevalence), while posttreatment
recurrence originate from distant minor subclones.13,84 The issue of
multiple cancer clones raises several clinical and technical questions:
How deep should sequencing be? What cut-offs should be used to
detect clonal abundance? How prevalent should a clone be to impact
patient care?
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There are no established guidelines to answer these questions in
the clinical context. Generally,WES aims for at least 100× coverage. To
conceptualize what this means clinically, consider the following exam-
ple: 100× coverage entails 100 reads at a given locus. If the tumor is
70% pure, then 70 of those reads represent tumor cells, and 30 reads
would be stromal. Assuming one tumor clone, a homozygous mutation
would therefore have 70 supporting reads and a heterozygous muta-
tion would have 35 reads. If there are two clones, one that represents
80%of cancer cells anda second that represents20%, thenmajor clone
would have 56 reads and the minor clone would have 14 reads. A het-
erozygous variant in the minor clone would therefore have seven sup-
porting reads.
Although the importance of subclones is well established, it is not
clear at what point subclones should be treated therapeutically. A tar-
getable ALK mutation in a major clone will surely be a good candi-
date for an ALK inhibitor, but what about an ALK mutation that is at
1% prevalence? Indeed, new evidence of subclonal ALKmutations sug-
gests that this question has growing importance for neuroblastoma.85
Furthermore, at 100× coverage, a heterozygous ALK mutation in 1%
of neuroblastoma cells will likely be missed due to insufficient read
coverage, but at 500× coverage, this same mutation may be detected.
Ultimately, additional research in this area is needed to help guide
precisionmedicine efforts.
7.6 Patient enrollment
Patient selection is critical for precision medicine. Patients for whom
cure rates are extremely high (e.g., standard-risk acute lymphoblas-
tic leukemia) may benefit less from tumor sequencing. Initial efforts
emphasized genomic profiling of multiply relapsed and refractory
patients. However, highly refractory tumors are unlikely to exhibit
single pathway addiction due to the development of multiple resis-
tance pathways during the course of therapy. Thus, many advocate for
genomic profiling early in disease course, ideally at diagnosis for cases
with higher probability of relapse, and to incorporate targeted therapy
(if appropriate) into the treatment regimen earlier as well, as tumors
that are more naïve may respond better to pathway inhibition. Many
groups are also repeating genomic analysis at the time of relapse to
assess for clonal evolution and newly acquiredmolecular features.
8 FUTURE DIRECTIONS
8.1 NCI PediatricMATCH study
TheNCIPediatricMolecularAnalysis forTherapeuticChoice (MATCH)
study, a collaborative effort between the Children’s Oncology Group
and NCI, is an ongoing effort that aims to build on adult oncology
study86,87 to develop a protocol for targeted therapy using an umbrella
design. NCI Pediatric MATCH will use standardized DNA- and RNA-
basedbiomarker profiling of patient tumor andblood samples to assign
patients to phase-II studies of targeted therapies if one of a predefined
set of actionable mutations is detected. A number of drug-biomarker
pairs have been prioritized for inclusion on the study based on the
factors including (i) prevalence of the genomic alteration in pediatric
cancer, (ii) ability to detect the target using the study platform, (iii)
evidence linking the target to activity of the agent, (iv) clinical and
preclinical data for specific agents, and (v) other ongoing or planned
biomarker-defined clinical studies. The study is anticipated to open
with five to eight arms (molecularly targeted agents). Given the size of
the NCI Pediatric MATCH study, the methods employed for genomic
profiling are likely to inform precision oncology approaches for pedi-
atric patients moving forward.
8.2 Liquid tumor biopsies
Currently, the clinical standard is to monitor genomic alterations via
direct tumor biopsy or resection. However, there is abundant evi-
dence that circulating tumor cells (CTCs) and/or cell-freeDNA (cfDNA)
present in blood offer an opportunity to evaluate tumor biology non-
invasively, even for brain tumors.88–93 In pediatric cancers, most evi-
dence for CTCs and cfDNA has been in neuroblastoma and other solid
tumors.94–96
In addition to being noninvasive, CTCs and cfDNA enable frequent
monitoring of tumor course during and after treatment. Technically,
methods to isolate this genomic material are challenging, costly, and
labor-intensive. However, they are increasingly clinically feasible.89
CTCs also entail single-cell sequencing, which if done for populations
of tumor cells, may enable more direct quantification of tumor hetero-
geneity and clonal abundance. In future, methodological advances and
decreasing sequencing costs may help advance clinical prospects for
single-cell sequencing.
8.3 Tumor profiling atmultiple time points
In addition to tumor profiling at diagnosis and relapse, some groups
now advocate for molecular analyses at more regular intervals dur-
ing treatment. Molecular assays for minimal residual disease (MRD)
in leukemias, for example, now include both flow cytometry and poly-
merase chain reaction. Sequencing may ultimately fulfill this role too,
and multiple groups are exploring the clinical feasibility and utility of
sequencing forMRD.97–100
8.4 Expanding the landscape of sequencing
As knowledge of tumor biology advances and sequencing becomes
more easily implemented, the range of clinically relevant genomic tools
may expand (Fig. 3).101 DNA methylation sequencing, or other forms
of epigenomics, may be appropriate for some tumors such as brain
tumors.Here, recent elucidationof aCpG islandmethylator phenotype
has advanced our understanding of tumor subgroups and may be rel-
evant to understanding driver genomic alterations102,103 and patient
disease course.104 Methylation sequencing may ultimately be possible
from noninvasive sources as well.105
Moreover, as immunotherapy and cancer immunology advance,
clinical sequencing may incorporate efforts to decode tumor
neoantigens and T-cell repertoires in patients. Such initiatives
are already being explored in patient samples and in actively treated
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F IGURE 3 Future directions in precision medicine. In upcoming
years, further researchmay define clinical roles for multiple new areas
of precision medicine. Four potential new areas include epigenomic
profiling, small RNA profiling, neoantigens, and epitope profiling, and
single cell sequencing and cell-free DNA (cfDNA)
patients.106–108 Further efforts in patient care may expand into small
RNA andmicroRNA sequencing.109
8.5 Rationally understanding drugmetabolism
One of the biggest black boxes in medicine is how different patients
metabolize medications, which can significantly impact effect dose,
therapeutic levels, and side effects. This is particularly critical for
cytotoxic chemotherapy (e.g., 6-mercaptopurine, methotrexate, and
cisplatin) as well as specific toxicities associated with individual
therapies (e.g., cardiomyopathy with anthracyclines and hearing loss
with vincristine). The application of genomic technologies, especially
metabolomics, may provide key insights as well as clinical tools to
understand and rationally predict drug behavior and toxicity profiles in
patients in vivo.110 Ultimately, patients may have individually tailored
dosing regimens based on their specific physiology. Such prospects
have the possibility of dramatically changing the way medicine is
practiced.
9 CONCLUDING REMARKS
Precision medicine has rapidly become one of the most pursued
research and clinical objectives over the past decade. The politi-
cal landscape, including the PMI and Moonshot for cancer, indicates
that funding and support for PMIs will continue to be robust. Early
clinical evidence for pediatric precision medicine through the PEDS-
MIONCOSEQ, BASIC3, INFORM, and iCat studies has been encourag-
ing, with meaningful results for some patients. Yet, precision medicine
still faces numerous challenges in its implementation, standardization,
and feasibility across multiple institutions. In the near future, large-
scale prospective consortia studies, such as the NCI Pediatric MATCH
study, will further refine the implementation of precision medicine in
pediatric oncology.
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